About the Company

surface oncology was created to advance next‐generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno‐biology. the company’s scientific founders and sab are comprised of world‐leading immunologists and cancer researchers, including co‐chairs sasha rudensky (memorial sloan kettering) and arlene sharpe (harvard/dfci). they are joined on the sab by christopher hunter and john wherry (university of pennsylvania), carla rothlin (yale university), elliott sigal, and john stagg (university of montreal). surface oncology recently completed a $35 million series a financing round with a-list backers. atlas venture, which seeded the company in 2014, led the round, joined by new enterprise associates, fidelity biosciences, lilly ($lly) ventures, amgen ($amgn) ventures, novartis ($nvs) institute for biomedical research, and elliott sigal, the former head of r&d at bristol-myers. for more information, visit ww

Sector

Professional, Scientific, and Technical Services

Industry

Research and Development in Biotechnology

Employees

90

CEO

J. Jeffrey Goater

Exchange

NASDAQ

Website

https://www.surfaceoncology.com/